ACADIA Pharmaceuticals Profit Margin: -869.18%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACAD Profit Margin Rankings
| Overall | 1st percentile | 4383 of 4439 |
| Sector | 7th percentile | 434 of 471 in Healthcare |
| Industry | 14th percentile | 112 of 131 in Biotechnology |
ACAD Profit Margin Range, Past 5 Years
| Minimum | -702.65% | Dec 2006 |
| Maximum | -16.75% | Jun 2003 |
| Average |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these ACAD related companies
ACAD News
ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
Feb 06, 9:00AM Business Wire
Feb 06, 9:00AM Business Wire
ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
Jan 30, 9:00AM Business Wire
Jan 30, 9:00AM Business Wire
Unusual 11 Midday Movers 01/18: (UEPS) (CBRX) (AMSC) Higher; (COOL) (KUTV) (BXS) Lower
Jan 18, 2:12PM Street Insider
Jan 18, 2:12PM Street Insider
ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
Dec 07, 9:00AM Business Wire
Dec 07, 9:00AM Business Wire
ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
Nov 02, 9:00AM Business Wire
Nov 02, 9:00AM Business Wire
$ACAD http://stks.co/cCR Update. Bullish MACD crossover. At resistance and near 20MA. Just needs volume.
about 122 days ago by VexTrades
about 122 days ago by VexTrades
$ACAD http://stks.co/bHc Big volume expansion. MACD cross on deck. Watch this one. Alerted lastnight.
about 123 days ago by VexTrades
about 123 days ago by VexTrades
ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
Sep 21, 9:00AM Business Wire
Sep 21, 9:00AM Business Wire
$ACAD http://stks.co/Bau Former runner. Popped through the 20MA and out of a wedge with higher lows.
about 153 days ago by VexTrades
about 153 days ago by VexTrades
ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
Sep 06, 9:00AM Business Wire
Sep 06, 9:00AM Business Wire
ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
Aug 03, 9:00AM Business Wire
Aug 03, 9:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACAD | 1.80 | -0.01 | -0.55% | 95.04M |
| ANR | 21.04 | -1.36 | -6.07% | 4.76B |
| NPD | 2.32 | 0.15 | 6.91% | 239.26M |
| TSU | 27.63 | 0.01 | 0.04% | 11.50B |
| VECO | 28.36 | 0.08 | 0.28% | 1.10B |
| TMK | 47.20 | 0.53 | 1.14% | 4.81B |
| FTWR | 0.19 | -0.03 | -12.44% | 9.43M |
| BDX | 76.42 | -0.43 | -0.56% | 16.32B |
| GCI | 14.61 | -0.42 | -2.79% | 3.48B |
| GOOG | 605.91 | -5.55 | -0.91% | 196.25B |
